UK markets open in 6 hours 55 minutes

Genomic Vision Société Anonyme (0QT4.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.0571-0.0249 (-30.37%)
At close: 05:23PM GMT
Full screen
Previous close0.0820
Open0.0000
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.0000 - 0.0000
52-week range
Volume16,965
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)-0.07
PE ratio (TTM)N/A
EPS (TTM)-0.1000
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Genomic Vision’s cutting-edge TeloSizer® application to be used in cancer research

    GENOMICS | GENETICS | R&D | DIAGNOSIS TESTS Genomic Vision’s cutting-edge TeloSizer® application to be used in cancer research Genomic Vision and CNRS launch a core oncology program with the Cancer Research Center of Marseille to develop companion tests based on TeloSizer® Bagneux (France) – Genomic Vision (FR0011799907 – GV, the “Company”), a Euronext-listed biotechnology company that develops tools and services for the highly accurate characterization of DNA sequences, is pleased to announce a

  • Business Wire

    Genomic Vision and Cambridge Consultants, Part of Capgemini, Announce the Development of an Innovative Technology Platform for In-depth Genomic Analysis

    BAGNEUX, France & CAMBRIDGE, England, November 07, 2022--Regulatory News: Genomic Vision (FR0011799907 – GV, – the "Company") (Paris:GV), a Euronext-listed biotechnology company developing tools and services for the highly accurate characterization of DNA sequences, is pleased to announce the selection of Cambridge Consutants, a world-leading product development and technology consultancy, part of Capgemini Invent1, to jointly develop the next generation of a technology platform for the analysis

  • Business Wire

    Genomic Vision: Financial Information for the Third Quarter of 2022

    BAGNEUX, France, October 27, 2022--Regulatory News: Genomic Vision (FR0011799907 – GV, – the "Company") (Paris:GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announced its revenue and cash position for the nine-month ended on September 30, 2022.